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As a tool for the epidemiologist and a translational exten-
sion for the geneticist, Mendelian randomization (MR) has
been exemplary and has been able to unify otherwise dis-
connected research specialties and show the genuine utility
of genetic association studies. With this, the demand for
and development of MR have of course brought with them
a smoothing or facilitation of existing analytical process.
What was once the reserved analytical space of a limited
number of experts is now a burgeoning, semi-automated,
plug-and-play approach to causal inference. This of course
is to be praised in that applied methods are being used and
accessed by many researchers and, with this, pertinent
questions are being addressed. However, what is also true
is that as we learn more about the source of genetic associ-
ation signals and the complicating effects that our own
favourite complex phenotypes might impart, the more we
need to advise caution in inference. This does not mean
that we should remove applied genetic epidemiology from
the quiver of the analyst, rather that in the era of prolifera-
tion of genetic analysis we should remain critical and not
allow the success of MR to become its own worst enemy.
Into this context Swerdlow et al.1 have delivered a
much needed examination of the factors which need to be
considered when embarking on an MR study. Their paper
‘Selecting genetic tools for Mendelian randomization in the
wake of genome-wide association studies’ discusses a series
of important considerations when forming an MR study if
working from the now substantial pools of genome-wide
association study (GWAS) results that are available for
causal pathway breakdown. Until relatively recently, MR
studies have generally focused on a limited number of
intermediate phenotypes. Recent applications of ‘omic’
technologies into large-scale population-based studies
present new opportunities for identifying predictive bio-
markers and causal links between established phenotypes
and disease outcomes.2–5 Whereas there is no guarantee
that use of multi-omic phenotype data will avoid any of
the problems encountered in observational epidemiology,
in combination with MR approaches there is an opportu-
nity to undertake informative analyses which exploit
genetically tractable intermediate phenotypes/biomarkers
and to potentially identify novel predictive biomarkers and
causal links between established phenotypes and disease
outcomes.4,6
Swerdlow et al. focus on important factors when select-
ing genetic variants to act as proxy measures for exposures
or intermediate phenotypes of interest. In contrast to direct
measurement, germline genotypes reliably associated with
risk factors can act in this role and offer several advan-
tages: genotypes are relatively easy to measure, they are
stable through time and between tissues (though their
effects may not be), they are largely immutable and are not
correlated with confounding factors as a result of the
mechanisms of Mendelian inheritance.7,8 Important issues
considered when choosing genetic variation to employ in
MR studies include the nature of the original GWAS signal
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(including the frequency and effect size of the relevant
mutation) and the specificity of the genetic effect which is
being exploited to yield a causal estimate. The former of
these is of course acknowledged as a function of the genetic
architecture of any given exposure or intermediate pheno-
type; however, the authors appropriately note that non-
specificity of genetic effect can be derived from a number
of sources including horizontal pleiotropy, biological com-
plexity and complex pathway or regulatory systems. In
light of this, a guiding set of rules or advice is provided in
efforts simultaneously both to make the potential MR ana-
lyst aware of the issues in question and also to offer sup-
port in the undertaking of this type of applied analysis.
The one area which remains important and perhaps
should be highlighted even more is the potentially damag-
ing impact of apparently informed instrument selection. If
one thing was learned from the exciting era of GWAS, it
was that the best conceived ideas about which loci would
contribute specifically to health outcomes of interest were
largely incorrect and that the hypothesis-free nature of
GWAS was the master stroke. To this end, I would com-
mend the efforts of the current paper for guiding MR anal-
yses, but would encourage the authors to go further. It is
unlikely that our current and limited appreciation of
genetic architecture (i.e. the shape of the underlying genetic
contribution to a phenotype of interest—here biomarkers
for causal analysis) is going to reflect the complete and
uncomplicated nature of genetic association. With this, the
notion of being able to assign biological function and reli-
able labels or filters for pleiotropy or pathway effects is
likely to be, at best, as reliable as our ability to measure
complex biology. Marking the direction of travel for
advanced MR analyses (highlighted by Swerdlow et al.),
analysis methods which are aware of limitations and the
likely invalidities of instrumentation (and which make no
assumptions about being able to filter these out), are likely
to be the way forward. A seminal paper published in this
journal in June 2015 marked a real step forward and (out-
side the realm of defined functional biology) leaves a last-
ing message: standardized rules for instrument choice may
bring awareness and sensible checks, but flexible and
robust methods born of an understanding of our limita-
tions may be the future for MR.9
Clearly, MR analyses are a positive contribution in this
era of deep phenotyping and genetic association studies,
but it is also important to state that they are not the only
source of evidence. Combinatorial investigations incorpo-
rating multi-omic examination of patients, population-
based analyses and interventions will be essential to the
future breakdown and understanding of causal pathways.
In this manner, triangulation of evidence remains the tried
and tested gold standard, though guided and appropriate
MR will offer a major contribution.
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